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OBJECTIVES We sought to investigate the relationship between the plasma concentration of brain
natriuretic peptide (BNP), echocardiographic findings and the clinical outcome of patients
supported with ventricular assist devices (VADs) to determine the role of BNP as a predictor
for cardiac recovery.
BACKGROUND Ventricular unloading in patients with end-stage heart failure supported by VADs may lead
to myocardial recovery. The BNP is produced in the myocardium in response to chronic
volume overload, but the effects on it of ventricular unloading by VADs are largely unknown.
METHODS Twenty-one patients diagnosed with nonischemic cardiomyopathy and supported by VADs
were evaluated for echocardiographic data and blood chemistry including BNP. They were
divided into patients who died while on mechanical support (group I; n  9), patients who
were transplanted (group II; n 8) and patients who were successfully weaned off the system
and did not require transplantation (group III; n  4).
RESULTS Brain natriuretic peptide plasma concentrations decreased significantly after initiation of
mechanical circulatory support (p  0.017). Furthermore, the changes in BNP plasma
concentrations showed a faster decrease to normal levels within the first week after
implantation of the VAD in patients who were weaned off the system (group III) compared
to patients in group I and group II.
CONCLUSIONS This study shows that ventricular unloading with VADs decreases BNP plasma concen-
trations in patients who suffer from end-stage heart failure. Furthermore, we hypothesize
that an early decrease of BNP plasma concentration may be indicative of recovery of
ventricular function during mechanical circulatory support. (J Am Coll Cardiol 2001;38:
1942–9) © 2001 by the American College of Cardiology
Mechanical circulatory support systems have improved the
clinical outcome of patients who suffer from end-stage heart
failure (1,2). It has been widely confirmed that mechanical
circulatory support is a suitable therapy as a bridge to
transplantation for patients with cardiac arrest, cardiogenic
shock or severe hemodynamic instability (3). The use of
mechanical circulatory support systems enables the patient
to recover from multiorgan failure. While using this bridg-
ing concept, numerous investigators have observed a recov-
ery of cardiac function after prolonged ventricular unloading
by mechanical circulatory assistance. Prolonged ventricular
unloading appears to help in the restoration of myocardial
function and thereby allows some hearts to subsequently
function without mechanical circulatory assistance or the
need for heart transplantation. However, the mechanisms of
cardiac recovery and the patient characteristics are not fully
known. Understanding the pathophysiologic mechanisms is
of interest for the field and may lead to new therapeutic
strategies and selection criteria for patients who suffer from
end-stage heart failure (4–6).
Currently, echocardiography is the most widely used
method for the detection of cardiac recovery in patients
supported with mechanical circulatory support systems (7).
In addition, numerous predictors of sustainable myocardial
and functional recovery are currently under investigation.
Natriuretic peptides (brain natriuretic peptide [BNP],
and atrial natriuretic peptide, [ANP]) are produced in the
myocardium in response to chronic volume overload. Both
BNP and ANP circulate in the plasma and defend the heart
against volume overload by decreasing salt and water reten-
tion and inhibiting vasoconstrictor peptides (8). In patients
who suffer from congestive heart failure, the concentrations
of natriuretic peptides and especially the concentration of
BNP, which is a ventricular hormone, correlate with the
status of ventricular dysfunction, and high concentrations
predict poor long-term survival (9,10).
In this study we investigated the relationship between
plasma concentrations of natriuretic peptides (BNP and
ANP), echocardiographic findings and clinical outcome so
as to determine the potential role of BNP as a predictor for
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cardiac recovery after prolonged ventricular unloading in
patients supported by mechanical circulatory support sys-
tems.
METHODS
Study design and recruitment of patients. We studied 21
patients who presented at the Department of Cardiotho-
racic and Vascular Surgery, German Heart Institute Berlin,
between October 1, 1997, and July 30, 1999, according to
the guidelines of the Committee on Human Investigation at
our institution. Patients suffered from end-stage nonisch-
emic cardiomyopathy and were treated with mechanical
circulatory support systems. Seven patients with end-stage
nonischemic cardiomyopathy were supported with a Nova-
cor left ventricular assist device (LVAD) (Baxter Health-
care, Oakland, California), 2 patients with an LVAD
(Berlin Heart, Berlin, Germany) and 12 patients with a
Berlin Heart biventricular assist device (BVAD). Initial
screening criteria for the implantation of an LVAD in-
cluded the following:
1) nonischemic cardiomyopathy (angiography);
2) refractory cardiogenic shock (cardiac index 2.0 l/min
per m2 with systolic blood pressure 95 mm Hg and
pulmonary wedge pressure 20 mm Hg and dependent
on high-dose inotropes or cardiac arrest; and
3) acceptable right ventricular function shown by trans-
esophageal echocardiography (TEE).
Patients additionally suffering from severe right heart
failure (central and peripheral edema and echocardiographic
evidence of right ventricular dilation with a right ventricular
ejection fraction 20%) underwent placement of a BVAD.
The device selection criteria have been previously described
by Loebe et al. (11). Patients were retrospectively divided
into three groups on the basis of postmechanical circulatory
support outcome. Group I consisted of patients who died
while on mechanical circulatory support. Group II con-
sisted of patients who could not be weaned and then were
bridged to heart transplantation, and group III consisted
of patients who could be weaned off mechanical circula-
tory support. Patients in group III were weaned off the
circulatory support because cardiac function had recov-
ered based on echocardiographic data obtained during
the weaning protocol.
Plasma samples for determination of standard blood
chemistry and natriuretic peptides were taken directly before
the implantation of a mechanical circulatory support system
and following a standard protocol after implantation of a
ventricular assist system (first postoperative day; first post-
operative week; second postoperative week; third postoper-
ative week; fourth postoperative week; every four weeks)
until the patient underwent heart transplantation or could
be weaned off the system or died during circulatory support.
All patients underwent regular echocardiographic examina-
tion to detect ventricular recovery while supported by an
LVAD or a BVAD. In addition, the preoperative and
postoperative administration of inotropes was analyzed
(inotrope administration for longer than seven days after
implantation of the assist device).
Quantitative analysis of natriuretic peptides. Plasma
BNP and ANP levels were determined in blood samples
before and after implantation of the mechanical circulatory
support system. All samples were taken by one physician
from a peripheral vein at the same time (in the morning).
Brain natriuretic peptide and ANP contents were deter-
mined by a semiquantitative analysis of blood samples.
Biochemical analysis for BNP content was performed ac-
cording to the method of Patrono et al. (12) using a kit
(Peninsula Laboratories, San Carlos, California). Biochem-
ical analysis for ANP content was carried out according to
the method of de Bold et al. (13) with a kit (Immundiag-
nostik, Bensheim, Germany). The intraassay variability was
4% to 6%. Investigators who were blinded to the sample
source performed the biochemical analysis.
Statistical analysis. The quantitive data are presented as
mean  SD. Comparisons among groups were calculated
using the Kruskal-Wallis H-test and the Pearson chi-square
test for nonparametric data. Comparisons of BNP values
and ANP values before assist implantation and eight weeks
after implantation of circulatory support systems were per-
formed using the Wilcoxon signed rank test. Statistical
significance was defined as p  0.05. Because of various
circumstances, including death, transplantation and wean-
ing of the patients over the follow-up period, the number of
patients was too small to test for differences over the entire
follow-up period and to test for group effects and interaction
terms.
RESULTS
Patient demographics. Demographic data are shown in
Table 1. No significant differences existed in age or gender
among the groups, and the cause of end-stage heart failure
was nonischemic cardiomyopathy in all cases. The age range
was from 3 months to 60 years, and the duration of
mechanical circulatory support varied in the groups (group
I: 1 to 559 days; group II: 2 to 601 days, and group III: 13
to 224 days). Nine patients underwent placement of an
LVAD system and 12 patients were supported by a BVAD
system. Of the nine patients in group I, four were placed on
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
BVAD  biventricular assist device
LVAD  left ventricular assist device
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
TEE  transesophageal echocardiography
VAD  ventricular assist device
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the LVAD system (Novacor, n  3; Berlin Heart, n  1)
and five patients on a BVAD. In group II, two patients
received an LVAD (Novacor) and six patients were sup-
ported by a BVAD. Of the four patients who were succes-
fully weaned off the device, three patients were supported
with an LVAD system (Novacor, n  2; Berlin Heart, n 
1) and one patient with a BVAD. In group I, eight patients
died of multiorgan failure and one other died of thrombo-
embolic complications. No difference was seen among the
groups concerning the pre- and postoperative administra-
tion of inotropes. In groups I and III all patients received
inotropes preoperatively, and in group II, seven of eight
patients received inotropes. Moreover, in group I, eight of
nine patients, in group II, five of eight patients, and in
group III, three of four patients received inotropes postop-
eratively. All patients who were weaned off the device were
discharged.
Decreased plasma concentrations of natriuretic peptides.
BNP. As shown in Figure 1A, we found higher plasma
concentrations of BNP before the implantation of a me-
chanical circulatory support system in all patients when
compared with BNP levels during circulatory support.
A significant decrease of plasma BNP levels occurred
within eight weeks after implantation of the ventricular
assist device (VAD) (p  0.02). Patients in group I
(1,650  770 pg/ml) and group II (2,080  1,400 pg/ml)
had higher BNP levels preoperatively compared with pa-
tients in group III (1,080  740 pg/ml). Furthermore, we
found a faster reduction of BNP levels within the first
week after implantation of VAD in patients who were
Table 1. Patients’ Demographic Data
Patient/Group
Gender/Age
(yrs)
NYHA
Functional Class
(preoperatively)
Mechanical
Circulatory
Support Systems
Implant
Duration
(d) Reason for Explantation
Patient 1/III M/33 III LVAD
(Novacor)
57 Cardiac recovery
Patient 2/III M/58 IV LVAD
(Berlin Heart)
224 Cardiac recovery
Patient 3/III M/42 IV LVAD
(Novacor)
62 Cardiac recovery
Patient 4/III M/2 IV BVAD
(Berlin Heart)
13 Cardiac recovery
Patient 5/II M/42 III–IV LVAD
(Novacor)
601 Heart transplantation
Patient 6/II F/31 III–IV BVAD
(Berlin Heart)
75 Heart transplantation
Patient 7/II F/14 III–IV BVAD
(Berlin Heart)
112 Heart transplantation
Patient 8/II M/47 III BVAD
(Berlin Heart)
413 Heart transplantation
Patient 9/II F/60 III–IV BVAD
(Berlin Heart)
348 Heart transplantation
Patient 10/II M/47 III LVAD
(Novacor)
575 Heart transplantation
Patient 11/II M/57 IV BVAD
(Berlin Heart)
410 Heart transplantation
Patient 12/II M/53 III–IV BVAD
(Berlin Heart)
2 Heart transplantation
Patient 13/I F/46 III–IV BVAD
(Berlin Heart)
559 Patient died during circulatory support
Patient 14/I M/50 III–IV BVAD
(Berlin Heart)
11 Patient died during circulatory support
Patient 15/I M/57 III BVAD
(Berlin Heart)
11 Patient died during circulatory support
Patient 16/I M/47 III LVAD
(Novacor)
30 Patient died during circulatory support
Patient 17/I M/45 IV LVAD
(Berlin Heart)
13 Patient died during circulatory support
Patient 18/I M/59 III–IV BVAD
(Berlin Heart)
23 Patient died during circulatory support
Patient 19/I M/35 IV LVAD
(Novacor)
23 Patient died during circulatory support
Patient 20/I F/14 IV LVAD
(Novacor)
1 Patient died during circulatory support
Patient 21/I F/33 IV BVAD
(Berlin Heart)
15 Patient died during circulatory support
BVAD  biventricular assist device; LVAD  left ventricular assist device; NYHA  New York Heart Association.
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weaned off the system compared with patients in groups I
and II (Fig. 1B).
ANP. We found higher plasma levels of ANP before the
implantation of a mechanical circulatory support system
compared with ANP levels during circulatory support.
However, no significant differences surfaced over the
follow-up period or between the groups (Fig. 2A and
2B).
EHOCARDIOGRAPHIC FINDINGS. Table 2 shows the echo-
cardiographic findings before implantation of a mechanical
circulatory support system and the most up-to-date echo-
cardiographic data directly before a patient underwent heart
Figure 1. (A) Higher plasma concentrations of brain natriuretic peptide (BNP) before the implantation of an assist device in all patients when compared
with BNP levels during circulatory support. *p  0.05 between groups. (B) Reduction of BNP plasma levels within the patient groups.
1945JACC Vol. 38, No. 7, 2001 Sodian et al.
December 2001:1942–9 BNP in Patients Supported by Mechanical Circulatory Assist Systems
transplantation or was weaned off the system or died during
circulatory support. Patients in group III showed adequate
ventricular function at the time of device explantation and
had a significant increase of the left ventricular ejection
fraction (LVEF) (p  0.048) (mean LVEF [group III]
before implantation of the system 17  2%; mean LVEF
before the explantation of the system 61  5%) compared
with patients in group I (mean LVEF before implantation
of the system 19 6%; mean LVEF before the patient died
35  14%) and group II (mean LVEF before implantation
of the system 15  5%; mean LVEF before the patient
underwent heart transplantation 33  6%).
DISCUSSION
It has been widely confirmed that implantable mechanical
circulatory support systems have improved the survival of
patients suffering from end-stage heart failure who are
Figure 2. (A) Atrial natriuretic plasma concentrations in all patients during circulatory support. (B) Atrial natriuretic plasma levels within the patient groups.
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awaiting heart transplantation and of those who can be
successfully weaned off the system to continue a normal life
without the necessity of heart transplantation (14,15).
The strategy of weaning patients off the system is
relatively new and little is known about the optimum
selection criteria and monitoring of patients who could be
potential candidates for weaning from mechanical circula-
tory assistance. Currently, the decision as to whether a
patient should be weaned off the system is mainly based on
echocardiographic data (16,17). Meanwhile, an increasing
number of investigators have reported morphological, bio-
chemical and immunological mechanisms that may be
responsible for recovery of cardiac function after prolonged
assistance with a mechanical circulatory support device
(18–20). Several groups hypothesize that long-term ventric-
ular unloading by the implantation of an LVAD or a
BVAD reduces the stress on the failing myocardium and
may lead to the reversal of cellular abnormalities in nonisch-
emic cardiac muscle. This has been suggested even for
patients who suffer from end-stage cardiomyopathy (21,22).
Usefulness of repeated measurements of neurohumoral
peptides in patients supported with mechanical circula-
tory assist systems. To find a potential predictor or a
parameter for adequate ventricular unloading, we investi-
gated the potential role of natriuretic peptides as physiolog-
ical regulators of hypertension and plasma volume expan-
sion. Both BNP and ANP have similar cardiovascular
effects, which include reduction of cardiac preload through
action in the brain, adrenal glands, kidneys, and vasculature.
Both circulate in the plasma, and the concentrations corre-
late with the degree of ventricular dysfunction, especially the
level of BNP, which is mostly synthesized in ventricular
myocardium. Increased plasma levels of BNP were found in
patients who had only mild heart disease (New York Heart
Association [NYHA] functional class I to II), which sub-
sequently worsened during the follow-up period (23,24).
Moreover the BNP plasma concentrations were reported to
be correlated with a decrease of LVEF and an increase of
left ventricular end-diastolic pressure (25). Therefore, BNP
might be a better marker than ANP for failing myocardium
and might potentially predict the progression of the disease,
which could help in its early diagnosis.
Accordingly, we hypothesized that prolonged and opti-
mal ventricular unloading by mechanical circulatory support
may lead to decreased plasma levels of natriuretic peptides
and especially a decrease of BNP concentrations, which are
pathophysiologically relevant to disease progression and
clinical outcome.
In this study we demonstrated that prolonged ventricular
unloading by mechancal circulatory assistance leads to
decreased concentrations of peripheral natriuretic peptide
levels and even to a significant reduction of BNP plasma
levels within the first two months after implantation of the
system. This may be caused by a reduction of ventricular
volume overload by mechanical circulatory support. The
reduction of volume-induced stress to the myocardial cells
may regulate the expression of certain genes, cytokines and
peptides as previously reported by other investigators (26–
28). Moreover, our results showed that in patients who
could be weaned off the system, the preoperative BNP
plasma levels were only 50% of the BNP plasma levels of
patients who underwent heart transplantation or who died
while on support. Patients in group III also showed a faster
reduction of BNP levels than that demonstrated in the
patients in group I and group II. These findings suggest that
patients with a relatively low plasma level of BNP are
theoretically in an earlier stage of heart failure and therefore
have a better chance for recovery from cellular abnormalities
after ventricular unloading by mechanical circulatory sup-
port. Additionally, one may hypothesize that a possibility
for recovery of cardiac function can be detected in an early
stage of circulatory support. To clarify this hypothesis, more
conclusive data will be necessary from the results of a larger
number of patients.
Study limitations and future perspectives in the treat-
ment of patients supported with mechanical circulatory
assist systems. The implication of our studies is not that
BNP is the sole parameter for indicating cardiac recovery,
but it may be an important and additional factor for the
selection of patients or for monitoring patients for adequate
ventricular unloading during mechanical circulatory assis-
tance. This parameter can be used as a potential marker of
cardiac recovery for the selection of patients who are
possible candidates for weaning off the system (e.g., device
Table 2. Echocardiographic Data
Echocardiographic
Parameters Group I Group II Group III p Value
LVEDD (mm) 75  19/61  18 77  17/62  13 68  15/45  15 NS
LVESD (mm) 66  18/49  17 68  21/55  18 61  18/31  9 NS
LVEF (%) 19  6/35  14 15  5/33  6 17  2/61  5  0.048
RVEDD (mm) 31  7/28  14 35  9/31  3 34  1/30  7 NS
RVESD (mm) 26  3/22  18 30  10/24  6 27  4/20  1 NS
RVEF (%) 34  6/31  3 26  16/41  6 31  8/52  17 NS
FS (%) 11  3/17  7 11  10/20  12 9  1/30  5 NS
Data are given as mean SD. Group I preimplantation/most up-to-date echocardiography before a patient was weaned off the assist device; Group II preimplantation/most
up-to-date echocardiography before a patient underwent heart transplantation; Group III  preimplantation/most up-to-date echocardiography before a patient died while
supported with an assist device.
FS  fractional shortening; LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular ejection fraction; LVESD  left ventricular end-systolic diameter;
RVEDD  right ventricular end-diastolic diameter; RVEF  right ventricular ejection fraction; RVESD  right ventricular end-systolic diameter.
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selection, surgical technique). In our institution, the deci-
sion as to whether a patient will be weaned off the system is
still based on clinical (e.g., NYHA classification) and
functional (e.g., echocardiography) data. These data were
most important among the patients studied with end-stage
nonischemic cardiomyopathy but could not predict whether
a patient would recover cardiac function during mechanical
circulatory support. In this regard, the plasma levels of
natriuretic peptides and especially BNP plasma levels can
also be an important marker for the detection of cardiac
recovery in an early stage and consequently be a marker for
the preselection of patients for weaning. Moreover, BNP
plasma levels could potentially be helpful in finding an
optimal time-point for the implantation of mechanical
circulatory support systems in patients suffering from end-
stage heart failure, ideally before multiorgan failure occurs
(29,30). For these patients a rapid BNP test is currently
under investigation in our institution.
Furthermore, a rapid BNP test could be beneficial in the
postoperative monitoring of patients supported with VADs
outside the hospital and might improve the long-term
follow-up by monitoring the current status of ventricular
unloading by the system. In the last few years only a small
number of reports about cardiac recovery under mechanical
circulatory support have been published (31,32). Most of
these were case reports, and worldwide there are only a few
patients who were weaned from mechanical circulatory
support without requiring heart transplantation. The num-
ber of patients in our study is small, which is certainly a
limitation, but the overall number of such patients world-
wide is also very small. Whether the observations reported
in this study can be extended to patients with ischemic
cardiomyopathy is not known. In our current study design
we decided not to include ischemic cardiomyopathies be-
cause of a different pathophysiology for end-stage heart
failure compared with patients suffering from nonischemic
cardiomyopathy. We hypothesize that the ischemic myo-
cardium has wide areas of fibrotic tissue and large scars,
which are potentially not able to recover and may not
synthesize neurohumoral peptides. This question has to be
clarified in future studies and is currently under investiga-
tion in our institution.
Conclusions. The data presented in our study support the
hypothesis that normalization of loading conditions in heart
failure patients with nonischemic cardiomyopathy leads to a
physiologic regulation of cytokines and peptides and may
restore myocardial function. Additionally, we showed that
relatively low preoperative levels of BNP may be an impor-
tant marker for cardiac recovery, and a reduction of plasma
BNP levels over the follow-up period may predict recovery
under ventricular unloading. To support these hypotheses
conclusively, more data from a larger number of patients are
necessary, and a more comprehensive study is currently
underway.
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